Akriti Jain, M.D

Akriti G Jain, MD treats myeloid disorders at Cleveland Clinic’s Main Campus in Cleveland, Ohio. She has a personal interest in taking care of patients with Myeloproliferative Neoplasms including Chronic Myeloid Leukemia. Her passion lies in understanding the needs of every patient and always prioritizing and advocating for her patients and their families. Her patient care philosophy involves offering in-depth explanation regarding diagnoses and to engage in active partnership with her patients and their referring providers to personalize decision-making and monitoring given the nature of the disorders she treats.

Dr. Jain trained at Dayanand Medical College and Hospital in Ludhiana, Punjab, India. After finishing medical school, she completed her residency at AdventHealth in Orlando where she also served as chief resident. Her keen interest in hematological malignancies started during medical school and continued to grow as she pursued residency. She joined Moffitt Cancer Center affiliated with the University of South Florida for further training in hematology and oncology. At Moffitt she worked with renowned mentors in the field of myeloid malignancies and gained in depth training and knowledge about treating these patients. Her research focus involves studying newly approved therapies for myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone marrow does not work well, and the bone marrow cells fail to make enough healthy blood cells. Myelo refers to the bone marrow. Dysplastic means abnormal growth or development. People with MDS have low blood cell count for at… (MDS), myeloproliferative neoplasms (MPNs) and acute leukemia (AML). She has presented her research at multiple conferences including at the American Society of Hematology and the John Goldman Conference on Chronic Myeloid Leukemia.

At Cleveland Clinic, she aims to continue to take care of each patient like family and to work on improving the treatment armamentarium for myeloid disorders.